Scinai Immunotherapeutics
SCNIScinai Immunotherapeutics Ltd. (NASDAQ: SCNI) is an Israel-based biopharmaceutical company. Its primary business focus is the development and manufacturing of antibody-based therapies. The company's activities are centered on two main sectors: biotech and immunotherapy. The company's pipeline is targeted toward specific therapeutic areas, namely infectious diseases and autoimmune disorders. Scinai operates a current Good Manufacturing Practice (cGMP) biologics manufacturing facility in Jerusalem, which supports its internal development programs. This facility is designed for the production of biologics, including monoclonal antibodies and other protein-based therapeutics. As a publicly traded entity, Scinai Immunotherapeutics reports its financial and operational progress through its listings on the NASDAQ Capital Market under the ticker SCNI and on the Tel Aviv Stock Exchange. The company's stated strategy involves advancing its proprietary research while also offering contract development and manufacturing organization (CDMO) services from its Israeli facility to generate revenue.
SCNI · Stock Price
Historical price data
About
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) is an Israel-based biopharmaceutical company. Its primary business focus is the development and manufacturing of antibody-based therapies. The company's activities are centered on two main sectors: biotech and immunotherapy. The company's pipeline is targeted toward specific therapeutic areas, namely infectious diseases and autoimmune disorders. Scinai operates a current Good Manufacturing Practice (cGMP) biologics manufacturing facility in Jerusalem, which supports its internal development programs. This facility is designed for the production of biologics, including monoclonal antibodies and other protein-based therapeutics. As a publicly traded entity, Scinai Immunotherapeutics reports its financial and operational progress through its listings on the NASDAQ Capital Market under the ticker SCNI and on the Tel Aviv Stock Exchange. The company's stated strategy involves advancing its proprietary research while also offering contract development and manufacturing organization (CDMO) services from its Israeli facility to generate revenue.